

TEST REQUISITION FORM



MOLECULAR GENETIC TESTING

PATIENT DETA	ILS		
(In BLOCK letters)			
Full Name			
DOB /	F Ethnicity		
E-mail ID Co	ntact No.		
Height			
REFERRING CLINICIAN (In BLOCK letters)			
Clinician Name Hospital			
E-mail ID Contact No			
SAMPLE DETA	ILS —		
Sample Type			
	/S (10-15 ug) DNA [1000 ng (20 ul x 50 ng)]		
Dried Blood Spot Others -	[Source:]		
Prenatal Sample: Gestational age wks days (* Maternal cell contamination is mandatory for any molecular tests - AF/CVS/POC/Cord Blood)			
Please indicate here if this sample needs a stat/urgent report(Rush charge may apply)			
TEST REQUEST	ED		
NGS based Tests (Tick appropriately: \square Single \square Duo \square Trio)			
ORION Single gene	ORION Focus		
(Requested forgene)	*Please contact lab for gene list & panel details		
ORION Scale up to ORION (Phenotype based Whole Exome (In case of Orion single gene	ORION Plus (Phenotype based Whole Exome + CNV		
+CNV Analysis) (Please specify Phenotype) Mitochondrial Genome Sequencing	Analysis + Mitochondrial Genome Sequencing) Whole Genome Sequencing		
Non NGS based Tests	whole defining dequaliting		
MLPA (Requested forgene) Digital PCR	Sanger Sequencing		
* Please contact lab for kit availability	(Requested forgene /		
Microarray 315K- Cytoscan Optima (Detects deletions upto 1Mb and	d duplications upto 2Mb in size)		
750K- Deepdive (Detects deletions and duplications upto 200kb in size)			
Others			

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059 Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com



TEST REQUISITION FORM

CLINICAL DIAGNOSIS

(Please provide detailed clinical information including age of onset of symptoms, disease progression, current status, response to treatment,

Clinical Details / Pedi	aree :	

presence of consanguinity, raminy history and relevant investigations performed.)			

Details of additional samples of other family members sent

(Relevant documents can be emailed to gc.ncgm@supratechlabs.com)

	Name	DOB / Age	Relationship (with patient)	Affected (Yes / No)	Details
1)					
2)					
3)					
4)					
4)					

Name:	Signature:
Relationship to Patient:	Date, Time and Place:
Clinician Name & Signature:	

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059 Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com



Patient Name: _

CONSENT/ASSENT FORM

Information on Genetic Testing	
Variations in human genes and chromosomes often lead to genetic disorders. Genetic to aim to identify these disease causing variations either in genes or chromosomes with re 1) Next Generation Sequencing (NGS) based testing allows simultaneous assessment of	spect to the patient symptoms and/or family history.
<u>Test Categories</u>	
 a) ORION (Single gene): Analysis is limited to protein coding regions of the gene of int b) ORION Focus*: Testing of a pre-designed set of disease specific genes. 	
c) ORION: A customized phenotype based analysis on a whole exome backbone. Or mitochondrial genes which are well associated with a particular phenotype/genes reque Copy Number Variations will be analyzed, however this may have to be validated by and	ested by your referring clinician are analyzed in this test.
d) ORION Plus: A customized phenotype based analysis on a whole exome backbone. O mitochondrial genes which are well associated with a particular phenotype/genes reque Copy Number Variations will be analyzed, however this may have to be validated by an sequencing is included in the analysis.	ested by your referring clinician are analyzed in this test. other non-NGS technology. Mitochondrial Genome
e) Scale upto ORION: In case of a negative ORION single gene report the test can be sc	
f) Whole Genome: Testing of coding as well as non coding portions of all the genes (appg) Mitochondrial Genome: Mitochondrial disorders originate from variants in nuclear DN pathological conditions. Mitochondrial genome testing involves testing of point mutation.	A or mitochondrial DNA (mtDNA) and result in a spectrum of ons within mitochondrial genome only.
 h) Trio Testing: Involves simultaneous genetic analysis by any of the above tests in three multiple samples are analyzed, a single comprehensive report will be issued for better u 	
Variant Interpretation & Test Results	
a) Variants are analysed, interpreted and scored according to a proprietary algorithm - 0 American College of Medical Genetics.	
b) Only variants related to the patient phenotype are reported. Benign and likely benigr	n variants are not reported.
c) Since the ACMG criteria are not purely objective, inter - laboratory variation in classifichange over time, subject to accumulation of scientific information. Hence it is requeste periodically, especially before contemplating prenatal testing or screening of "at risk" red) Data for variants unrelated to the phenotype can be provided to your health care pro	d to re-connect the laboratory for any new updates elatives.
Expected Test Results	
a) Positive: Detection of a disease causing pathogenic/likely pathogenic variation. Whil might NOT always translate into diagnosis as mentioned above. b) Negative: No variants related to patient phenotype were detected (refer to test limits)	
c) Variants of uncertain significance: Implies detection of a variant whose significance is	
Re-classification may be possible after segregation studies, ancillary testing, phenotype data in medical literature. It is recommended to contact the laboratory for periodic review prenatal testing / carrier screening.	evolution and accumulation of further variant specific/related
d) Copy number variation: Though the test analyzes phenotypically significant copy nur significance until confirmed by an alternative validated by an alternative Non-NGS test r	
e) Incidental Findings: Indicates the presence of variants in a designated set of genes as have been selected based on the benefit of early intervention. Variants in these genes a updated periodically by ACMG and may vary across reports analyzed at different time p pathogenic variants in these genes if desired. Analysis of incidental genes is performed	re usually unrelated to patient phenotype. The gene content is eriods. Currently the laboratory reports only pathogenic/likely
Limitations of Genetic Testing	
 a) A negative test result does not always exclude a genetic disorder. In some cases the t protein coding area because of limitation in technology/scientific information. 	
b) The current technology does not standardly analyze intronic variants, non-variant splice r Similarly coverage of gene promoters regions may not be uniform or universal.	
c) The accuracy of genetic test results is dependent of the information provided with re collection and transport. Contamination may interfere with results.	lation to biological relation, ship clinical history and sample
d) In rare cases due to insufficient DNA quantity or quality, a repeat sample may be requ	
 e) The laboratory usually ensures timely dispatch of reports, however certain unanticipaliable. 	ted delays may occur for which the laboratory cannot be held
The reports are released to your referring clinician as well as the patient/guardian (in c reports/ information regarding the results will not be released to any other person/clin	
☐ I have read and understood/have been explained the above in language of my unde	rstanding and permit NCGM to perform the recommended
genetic analysis. I understand that the data derived from my genetic testing may be stored indefinite	
stored in de-identified form. I understand my de-identified data/sample may be use presentations and publications. I do NOT consent to the reporting of incidental findings.	
Name	Signature:
Name:	orginatare.
Relationship to Patient:	Date, Time and Place:
Cliniaian Nama C Ciamatura	
Clinician Name & Signature:	

Guardian Name:

(In case of minor)